AltruBio, Inc.

Based in the US, AltruBio, Inc. is a biotechnology company focused on developing innovative therapeutics for immunological diseases, including Ulcerative Colitis and Psoriatic Arthritis. Founded in 2020 and headquartered in San Francisco, US, AltruBio, Inc. specializes in immunological therapies.

The company has raised a total of USD 225. 00 mn through multiple funding rounds, with the latest being a Series B round on May 21, 2024, led by BVF Partners. CEO Judy Chou oversees operations, having a background in biotech innovation. AltruBio specializes in developing innovative therapeutics targeting immunological diseases, with a primary focus on its lead product candidates, ALTB-268 and ALTB-168.

ALTB-268 is an advanced immunology product designed as a T-Cell Checkpoint Regulator Platform, aimed at treating conditions such as Ulcerative Colitis and Psoriatic Arthritis. The product has undergone various stages of clinical trials, demonstrating clinical efficacy in Phase II trials, with a Phase 2a trial for UC patients initiated in late 2023. AltruBio primarily targets healthcare providers and patients suffering from autoimmune diseases, focusing on improving patient outcomes in the immunology space. The company’s products are marketed in regions including North America and parts of Asia, specifically targeting healthcare systems familiar with advanced biopharmaceutical therapies.

AltruBio's revenue generation revolves around its clinical products, particularly ALTB-268 and ALTB-168, which are positioned for B2B transactions with healthcare institutions and pharmaceutical partners. Transactions typically occur through structured partnerships, enabling healthcare providers to access these novel therapies within clinical settings. The pricing structure involves agreements that may vary based on the specifics of clinical trial engagements or product distribution, potentially including direct sales to hospitals or inclusion in physician-administered treatment protocols. As the company advances its clinical trials, revenue streams may also be supplemented through collaborations with research entities or pharmaceutical firms, facilitating broader access to its proprietary treatments.

In May 2024, AltruBio, Inc. raised USD 225 mn in Series B funding, led by BVF Partners with participation from multiple investors. The company plans to utilize the funding to advance the clinical development of its novel immune checkpoint enhancer (ICE) PSGL-1 agonist antibody ALTB-268 and support ongoing and planned Phase 2 clinical trials in ulcerative colitis. AltruBio aims to expand its market presence, focusing on additional geographic regions in North America and Asia, while progressing the launch of its new products over the next few years.